Video

Dr. Levy on Positive and Negative Biomarkers for Immunotherapy in Lung Cancer

Benjamin P. Levy, MD, discusses biomarkers for immunotherapy in lung cancer.

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses biomarkers for immunotherapy in lung cancer.

Levy anticipates, in the future, a combination of biomarkers will serve as an indication for patients to receive immunotherapy in lung cancer. Research is currently looking into markers within plasma, such as tumor mutational burden. Currently, PD-L1 is used to help guide decisions with immunotherapy.

In addition to positive predictors of response, negative predictors must also be identified in lung cancer, says Levy. Data indicate that the mutations STK11 and KEAP1 may signify a negative response to immunotherapy, either as a single agent or in combination. Overall, research must continue to identify markers that represent favorability toward immunotherapy as well as avoidance, concludes Levy.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity